Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CSL ( (AU:CSL) ) has shared an announcement.
CSL Limited has announced an update on its ongoing share buy-back program, revealing that a total of 2,341,481 securities have been bought back prior to the latest update, with an additional 46,706 securities purchased on the previous day. This buy-back initiative is part of CSL’s strategy to optimize its capital structure and enhance shareholder value, reflecting confidence in the company’s financial health and future prospects.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$283.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, focusing on the development and manufacturing of innovative medicines and vaccines. The company is known for its work in plasma therapies, vaccines, and other specialty biopharmaceuticals, with a strong market presence globally.
Average Trading Volume: 1,199,314
Technical Sentiment Signal: Sell
Current Market Cap: A$88.37B
For detailed information about CSL stock, go to TipRanks’ Stock Analysis page.